Moderna Reports High Effectiveness in Late-Stage COVID-19 Vaccine Trial
Moderna reveals that its experimental COVID-19 vaccine demonstrates strong effectiveness at preventing the virus. This breakthrough adds a second highly viable candidate to the global pandemic response.
Moderna announces highly positive results from its late-stage clinical trial, showing that its COVID-19 vaccine is highly effective at preventing the illness. The data indicates an efficacy rate of 94.5 percent, providing a powerful new tool in the fight against the global pandemic.
This news arrives just one week after a similar announcement from Pfizer and BioNTech, confirming that multiple vaccine approaches successfully combat the virus. Moderna's candidate utilizes messenger RNA technology and reportedly remains effective even in older adults, who are particularly vulnerable to severe complications.
The company prepares to seek emergency use authorization from regulators in the coming weeks. Moderna states that its vaccine is easier to store and transport than some other candidates, which simplifies the logistics of large-scale distribution to hospitals and clinics worldwide.